CTKB — Cytek Biosciences, Inc.
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 1831915 ·
Last close
$4.44
Market Cap
$577.13M
52W High
$4.93
52W Low
$3.70
ADV30
808,433
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 48,140,000 | 28,340,000 | -11,400,000 | -12,158,000 | 446,934,000 | 73,846,000 | 124,980,000 |
| Mar 2026 | 44,135,000 | 21,254,000 | -18,463,000 | -18,866,000 | 449,113,000 | 65,665,000 | 121,469,000 |
| Dec 2025 | 62,141,000 | 32,885,000 | -5,594,000 | -44,076,000 | 461,542,000 | 90,853,000 | 119,803,000 |
| Sep 2025 | 52,293,000 | 27,551,000 | -9,192,000 | -5,478,000 | 494,919,000 | 93,281,000 | 116,348,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,039,000
Investing CF
$-2,976,000
Financing CF
$3,881,000
CapEx
$-6,133,000
Dividends Paid
—
Buybacks
$63,000
EPS Diluted TTM
$-0.62
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-132,761,000
Inventory
$52,251,000
Receivables
$51,297,000
ST Investments
$188,158,000
EBIT TTM
$-40,504,000
Pretax Income TTM
$-40,816,000
Interest Exp TTM
$312,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$206,708,992
EBITDA
$-39,761,000
Free Cash Flow
$9,295,375
Enterprise Value
$389,675,456
Total Cash
$262,004,000
Total Debt
$26,460,000
Shares Out
129,983,253
Trailing EPS
$-0.63
Book Value
$2.48
ROE
-23.0%
ROA
-6.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 201,493,000 | -40,384,000 | -66,539,000 | 461,542,000 | 119,803,000 | — | -4,686,000 |
| Dec 2024 | 200,453,000 | -20,523,000 | -6,020,000 | 499,500,000 | 103,763,000 | — | 25,379,000 |
| Dec 2023 | 193,015,000 | -27,845,000 | -12,148,000 | 494,457,000 | 101,393,000 | — | 5,281,000 |
| Dec 2022 | 164,036,000 | -1,804,000 | 2,576,000 | 519,476,000 | 93,930,000 | — | -12,231,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.07
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $4.44 · call volume: 5 · put volume: 1
Expected Move to 2026-10-16:
±$1.96
(44.14%) —
implied range
$2.48 –
$6.40
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MSIF | MSC INCOME FUND, INC. | $580.42M | $12.80 | — |
| NMCO | Nuveen Municipal Credit Opportunities Fund | $581.84M | $10.40 | — |
| IIM | Invesco Value Municipal Income Trust | $585.94M | $12.44 | — |
| ETJ | Eaton Vance Risk-Managed Diversified Equity Income Fund | $565.33M | $8.40 | — |
| NML | Neuberger Energy Infrastructure & Income Fund Inc. | $589.82M | $10.41 | — |
News headlines (Yahoo Finance, 1h cache)
Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
2026-08-21 20:35 · Yahoo
Cytek (CTKB) Q2 2026 Earnings Call Transcript
2026-08-12 23:29 · Yahoo
Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ...
2026-08-06 05:07 · Yahoo
Cytek Biosciences Q2 Earnings Call Highlights
2026-08-06 00:04 · Yahoo
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
2026-08-05 22:10 · Yahoo
Cytek Biosciences Reports Second Quarter 2026 Financial Results
2026-08-05 20:05 · Yahoo
Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026
2026-07-22 20:05 · Yahoo
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
2026-06-02 21:00 · Yahoo
Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement
2026-07-15 21:00 · Yahoo
Cytek Biosciences, Inc. Q2 2026 Earnings Call Summary
2026-08-06 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.